Filtered By:
Source: Oncology Letters
Cancer: Non-Small Cell Lung Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 26 results found since Jan 2013.
Upregulation of long non ‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib
In conclusion, the upregulation of LINC00460, the expression of which is implicated in osimertinib resistance, in the primary site and plasma of patients with EGFR mutation-positive lung cancer may be associated with a poor prognosis in those treated with osimertinib.PMID:37559586 | PMC:PMC10407845 | DOI:10.3892/ol.2023.13966
Source: Oncology Letters - August 10, 2023 Category: Cancer & Oncology Authors: Yuta Nakano Kazutoshi Isobe Takahiro Yoshizawa Naohisa Urabe Sakae Homma Kazuma Kishi Source Type: research
Targeting transient receptor potential canonical 1 reduces non ‑small cell lung cancer chemoresistance and stemness via inhibition of PI3K/AKT signaling
In conclusion, the results of the current study suggested that targeting TRPC1 could attenuate cancer stemness and chemoresistance via suppression of PI3K/AKT signaling in NSCLC.PMID:37153044 | PMC:PMC10157351 | DOI:10.3892/ol.2023.13810
Source: Oncology Letters - May 8, 2023 Category: Cancer & Oncology Authors: Jiahui Jin Xinyu Yan Yaru Zhao Haojie Zhang Kai Zhuang Yating Wen Jingjing He Junzhen Gao Source Type: research
Identification of potential circular RNA biomarkers in lung adenocarcinoma: A bioinformatics analysis and retrospective clinical study
Oncol Lett. 2022 May;23(5):144. doi: 10.3892/ol.2022.13264. Epub 2022 Mar 11.ABSTRACTNon-small cell lung cancer (NSCLC) is one of the leading causes of cancer-associated mortality. Lung adenocarcinoma (LAC) is the most prevalent pathological subtype of NSCLC and accounts for ~40% of all lung cancer mortalities. There remains an urgent demand for the identification of novel biomarkers for the diagnosis and development of therapeutic strategies for LAC. In the present study, the profiles of the differentially-expressed circular RNAs (circRNAs) in LAC tissues compared with those in their corresponding non-cancerous tissues we...
Source: Oncology Letters - March 28, 2022 Category: Cancer & Oncology Authors: Yonggang Zhu Feng Cao Fei Liu Sihua Liu Lingjiao Meng Lina Gu Hanjun Zhao Meixiang Sang Baoen Shan Source Type: research
Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib-resistant non-small cell lung cancer cells
Oncol Lett. 2021 Jul;22(1):556. doi: 10.3892/ol.2021.12817. Epub 2021 May 24.ABSTRACTPatients with non-small cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (TKIs) ultimately develop drug resistance and metastasis. Therefore, there is a need to identify the underlying mechanisms of resistance to EGFR-TKIs. In the present study, colony formation and MTT assays were performed to investigate cell viability following treatment with icotinib. Gene Expression Omnibus datasets were used to identify genes associated with resistance. Wound healing and Transwell assays were used to detect cell migration and inv...
Source: Oncology Letters - June 4, 2021 Category: Cancer & Oncology Authors: Yang Yang Yizhe Wang Xiaofang Che Kezuo Hou Jie Wu Chunlei Zheng Yang Cheng Yunpeng Liu Xuejun Hu Jingdong Zhang Source Type: research
Synergistic effects of olaparib combined with < em > ERCC1 < /em > on the sensitivity of cisplatin in non-small cell lung cancer
In conclusion, olaparib combined with ERCC1 expression may enhance the sensitivity of cisplatin in NSCLC. These findings may provide novel insight for the improvement of platinum drug sensitivity and treatment of NSCLC.PMID:33747222 | PMC:PMC7967929 | DOI:10.3892/ol.2021.12626
Source: Oncology Letters - March 22, 2021 Category: Cancer & Oncology Authors: Kejie Xie Xiaoyan Ni Shanmei Lv Guozhong Zhou Honger He Source Type: research
